c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Lung Cancer

• Publication date

  2008-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.LUNGCAN.2007.10.028PMID 18096271
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity

  2007cited by this paper
• Local application of antisense for prevention of restenosis.

  2005cited by this paper
• In vivo Bioavailability and Pharmacokinetics of a c-MYC Antisense Phosphorodiamidate Morpholino Oligomer, AVI-4126, in Solid Tumors

  2005cited by this paper
• Transcriptional regulation and transformation by Myc proteins

  2005cited by this paper
• Editorial [Hot Topic: Anti-Cancer Drugs Executive Editor: Elke Bergmann-Leitner]

  2005cited by this paper
• Endobronchial Metastases from Extrathoracic Malignancies

  2005cited by this paper
• Cancer therapeutics: targeting the dark side of Myc.

  2005cited by this paper
• Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics.

  2004cited by this paper
• Expression of Matrix Metalloproteinase-9 in Endothelial Cells Is Differentially Regulated by Shear Stress

  2003cited by this paper
• Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans.

  2003cited by this paper
• A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity

  2003cited by this paper
• Systemic targeted delivery of antisense with perflourobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model.

  2003cited by this paper
• Myc pathways provoking cell suicide and cancer

  2003cited by this paper
• Pharmacological inactivation of MYC for the treatment of cancer.

  2003cited by this paper
• Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model

  2003cited by this paper
• Prostate cancer: status of current treatments and emerging antisense-based therapies.

  2002cited by this paper
• Laser microdissection and gene expression analysis on formaldehyde-fixed archival tissue.

  2002cited by this paper
• c-myc antisense oligonucleotide treatment ameliorates murine ARPKD.

  2002cited by this paper
• Inhibition of human chorionic gonadotropin β‐subunit modulates the mitogenic effect of c‐myc in human prostate cancer cells

  2002cited by this paper
• Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats.

  2002cited by this paper
• Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens.

  2002cited by this paper
• New functions for the matrix metalloproteinases in cancer progression

  2002cited by this paper
• Local delivery of c‐myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model

  2001cited by this paper
• ALTERED MATRIX METALLOPROTEINASE EXPRESSION ASSOCIATED WITH ONCOGENE‐MEDIATED CELLULAR TRANSFORMATION AND METASTASIS FORMATION

  2001cited by this paper
• Antiproliferative Effects of Steric Blocking Phosphorodiamidate Morpholino Antisense Agents Directed against c-myc

  2000cited by this paper
• FISH Analysis of Gene Aberrations (MYC, CCND1, ERBB2, RB, and AR) in Advanced Prostatic Carcinomas Before and After Androgen Deprivation Therapy

  2000cited by this paper
• Evaluation of antisense mechanisms of action.

  2000cited by this paper
• c-Myc antisense limits rat liver regeneration and indicates role for c-Myc in regulating cytochrome P-450 3A activity.

  2000cited by this paper
• Antisense Morpholino Oligonucleotide Analog Induces Missplicing of C-myc mRNA

  1999cited by this paper
• Morpholino antisense oligomers: the case for an RNase H-independent structural type.

  1999cited by this paper
• A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.

  1999cited by this paper
• Morpholino and Phosphorothioate Antisense Oligomers Compared in Cell-Free and In-Cell Systems

  1997cited by this paper
• Morpholino Antisense Oligomers: Design, Preparation, and Properties

  1997cited by this paper
• Metastases: mechanisms, pathways, and cascades.

  1995cited by this paper
• Antisense Research and Applications

  1993cited by this paper
• Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16.

  1991cited by this paper

• Noncoding RNA (ncRNA)-mediated regulation of TLRs: critical regulator of inflammation in tumor microenvironment

  2025cites this paper
• Tumor-Selective Gene Therapy: Using Hairpin DNA Oligonucleotides to Trigger Cleavage of Target RNA by Endogenous flap endonuclease 1 (FEN 1) Highly Expressed in Tumor Cells.

  2025cites this paper
• Targeting Transcription Factors in Cancer: From "Undruggable" to "Druggable".

  2023cites this paper
• Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

  2023cites this paper
• Benzothiazole Derivatives Targeting G‐Quadruplex DNA: Synthesis, DNA Interaction and Living Cell Imaging

  2022cites this paper
• Non-Coding RNAs in Hepatocellular Carcinoma

  2022cites this paper
• Dormancy in Breast Cancer, the Role of Autophagy, lncRNAs, miRNAs and Exosomes

  2022cites this paper
• Advances in Nanoparticle mediated Targeting of RNA Binding Protein for Cancer.

  2022cites this paper
• Chrysin-Induced G Protein-Coupled Estrogen Receptor Activation Suppresses Pancreatic Cancer

  2022cites this paper
• Self-transfecting GMO-PMO and PMO-GMO chimeras enable gene silencing in vitro and in vivo zebrafish model and NANOG Inhibition Induce the Apoptosis in Breast and Prostate Cancer Cells

  2021cites this paper
• The Contribution of Autophagy and LncRNAs to MYC-Driven Gene Regulatory Networks in Cancers

  2021cites this paper
• Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic

  2021cites this paper
• The Role of Autophagy and lncRNAs in the Maintenance of Cancer Stem Cells

  2021cites this paper
• Polymalic Acid–Based Nanobiopolymer Provides Efficient Systemic Breast Cancer Treatment by Inhibiting both HER2/neu Receptor Synthesis and Activity

  2020cites this paper
• Designing Personalized and Innovative Novel Drug Therapies for Cancer Treatment

  2020cites this paper
• Internal Oligoguanidinium Transporter: Mercury Free Scalable Synthesis, Improvement of Cellular Localization, Endosomal Escape, Mitochondrial Localization and Conjugation with Antisense Morpholino for NANOG Inhibition to Induce Chemosensitisation of Taxol in MCF-7 Cells.

  2020cites this paper
• Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models

  2020cites this paper
• MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC

  2020cites this paper
• The role of MYC in the transformation and aggressiveness of ‘indolent’ B-cell malignancies

  2020cites this paper
• Splice-switching small molecules: A new therapeutic approach to modulate gene expression.

  2019cites this paper
• Noncoding RNAs in cancer therapy resistance and targeted drug development

  2019cites this paper
• RNA Binding Protein as an Emerging Therapeutic Target for Cancer Prevention and Treatment

  2017cites this paper
• Targeting the serrated pathway of colorectal cancer with mutation in BRAF.

  2016cites this paper
• Oligonucleotide-based theranostic nanoparticles in cancer therapy.

  2016cites this paper
• Targeting MYC in cancer therapy: RNA processing offers new opportunities

  2016cites this paper
• Establishment of a highly metastatic model with a newly isolated lung adenocarcinoma cell line.

  2015cites this paper
• Functional analysis of splicing mutations in the IDS gene and the use of antisense oligonucleotides to exploit an alternative therapy for MPS II.

  2015cites this paper
• Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility.

  2015cites this paper
• Lysine-specific demethylase 1 promotes tumorigenesis and predicts prognosis in gallbladder cancer

  2015cites this paper
• Antisense oligonucleotides: modifications and clinical trials

  2014cites this paper
• Increased invasiveness of MMP-9-deficient tumors in two mouse models of neuroendocrine tumorigenesis

  2013cites this paper
• Hypoxic Adaptation and Arsenic Trioxide Treatment in Small Cell Lung Carcinoma

  2013cites this paper
• Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes

  2012cites this paper
• Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer

  2012cites this paper
• c-Myc and Cancer Metabolism

  2012cites this paper
• Overview on applications of antisense-mediated exon skipping.

  2012cites this paper
• Efficacy of a Phosphorodiamidate Morpholino Oligomer Antisense Compound in the Inhibition of Corneal Transplant Rejection in a Rat Cornea Transplant Model

  2012cites this paper
• A Review of Antisense Therapeutic Interventions for Molecular Biological Targets in Various Diseases

  2011cites this paper
• Targeting Wnt Signalling in Cancer

  2011cites this paper
• Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity.

  2011cites this paper
• The ROCK signaling and breast cancer metastasis

  2011cites this paper
• HZ08, a great regulator to reverse multidrug resistance via cycle arrest and apoptosis sensitization in MCF-7/ADM.

  2010cites this paper
• Delivery of phosphorodiamidate morpholino antisense oligomers in cancer cells.

  2009cites this paper
• Inhibition of RNA virus infections with peptide-conjugated morpholino oligomers.

  2008cites this paper
• Open Access Research Article Development of a Highly Metastatic Model That Reveals a Crucial Role of Fibronectin in Lung Cancer Cell Migration and Invasion

  year unknowncites this paper